Project Grant R01MH134884
Award Date
9/5/24
Completion Date
7/31/29
Dollars Obligated
$731K
Federal Agency
National Institute of Mental Health
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $795,000 to the University of California, San Diego (UCSD) to conduct a multi-center, randomized clinical trial. The goal is to develop a Clozapine decision support tool using biomarkers to improve outcomes for first-episode psychosis (FEP) patients who are at risk of poor response to conventional first-line antipsychotics. The study will...
The National Institute of Mental Health (NIMH) awarded a Project Grant under the Mental Health Research Grants program (CFDA 93.242) to The Feinstein Institutes for Medical Research, a non-profit medical research organization, for $1,217,886 on September 5, 2024. The goal of this 5-year project is to develop a clozapine decision support tool for first-episode psychosis (FEP) patients based on three specific biomarkers: a functional brain scan, a genetics test for weight gain risk, and a genetics...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to develop a decision support tool for early introduction of clozapine treatment in first-episode psychosis (FEP) patients. The $779,842 award, effective September 5, 2024 through July 31, 2029, will fund a multi-center, randomized clinical trial to evaluate the efficacy of using biomarkers (functional brain scan, genetic tests for weight gain and...
This Project Grant award from the National Institute of Mental Health (NIMH), under CFDA 93.242 - Mental Health Research Grants program, provides $665,508 to the Centre for Addiction and Mental Health (CAMH) in Canada to conduct a multi-center, randomized clinical trial. The goal is to develop a clozapine decision support tool based on biomarkers to improve outcomes for first-episode psychosis patients who do not respond well to conventional first-line antipsychotics. The study will characterize...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to validate a predictive biomarker in the cerebellar-cortical circuitry for assessing treatment response to antipsychotic medication in patients with first-episode psychosis. The $519,558 award, granted on June 15, 2025, will support a 5-year research project conducted by The Feinstein Institutes for Medical Research. The key objectives are to: 1)...
This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 Mental Health Research Grants provides $508,500.00 to New York University to leverage electronic health records, dimensional phenotyping, and genetic analysis to build predictive models and identify subtypes of clinical outcomes among individuals with schizophrenia. The project aims to advance precision psychiatry by developing individualized treatment planning, outcome monitoring, and preventive...
The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...
The University of Pittsburgh is conducting a $420,685 project grant titled "Accelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment" funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). This two-year project seeks to explore the use of accelerated intermittent theta burst stimulation (iTBS) to enhance working memory and functional connectivity in individuals with treatment-resistant...
This Cooperative Agreement award, funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), supports a two-phase project to develop and test a biomarker-guided approach for selecting the most effective antidepressant treatment for individuals with treatment-resistant depression (TRD). The total funding amount is $2,754,722, with a project period from September 15, 2024 to September 14, 2026. In the initial UG3 phase, the project...
The National Institute of Mental Health (NIMH) awarded a $1,564,542 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of California, Los Angeles (UCLA) to advance precision psychiatry research. The 5-year grant, which commenced on September 1, 2024, aims to address key barriers to scalability, utility of genomic data, clinical application, and translation to clinical practice in the precision psychiatry paradigm. Specifically, the grant will fund the development of...